Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1

This is less a credible threat to the leaders than a reminder that obesity is evolving into a platform war, not a single-mechanism winner-take-most market. LLY and NVO have the advantage of distribution, payer relationships, and the ability to layer new agents onto existing regimens; that turns late entrants into “must be meaningfully better” stories rather than simple me-too optionality. VKTX therefore trades like a binary proof-of-concept asset, not a category contender, until it demonstrates either materially superior efficacy, cleaner tolerability, or a clearer path to combination use.

The second-order implication is that the market may be overpricing every new obesity mechanism as incremental upside to the franchise TAM. In reality, incumbents can use combination therapy to defend share and compress the addressable opportunity for standalone entrants; that likely lowers the terminal value of VKTX while modestly extending the duration of LLY/NVO’s growth runway. If payers start demanding step therapy or lower net prices as more agents arrive, the competitive moat shifts further toward manufacturers with the best manufacturing scale and rebate capacity, not the newest biology.

Near term, the catalyst path for VKTX is long-dated and data-dependent: phase 1 readthrough is only a sentiment event, while the real valuation check is whether efficacy/tolerability can justify a future combination role over the next 6-18 months. The thesis breaks if early human data show a clear safety or adherence edge versus incumbent combination strategies; if it does not, the stock should continue to de-rate on probability, not because obesity demand weakens but because the bar for relevance keeps rising.